Morpheus Research Report Alleges 'Anti-Competitive' Practices by MakeMyTrip Despite CCI Order

Morpheus Research Report Alleges 'Anti-Competitive' Practices by MakeMyTrip Despite CCI Order

The Hindu BusinessLine – Companies
The Hindu BusinessLine – CompaniesMar 31, 2026

Why It Matters

The claims suggest ongoing regulatory non‑compliance and financial opacity, which could trigger investor scrutiny and affect MakeMyTrip’s valuation ahead of a domestic IPO. Demonstrated adherence to competition law will be crucial for the firm’s growth strategy in India’s travel market.

Key Takeaways

  • MakeMyTrip fined $26 million by CCI in 2022.
  • Morpheus claims price‑parity enforcement continues via internal scores.
  • Report alleges accounting tricks and under‑provisioned GoAir receivable.
  • Company evaluating Indian listing after restructuring RedBus merger.
  • No comment obtained from MakeMyTrip for the allegations.

Pulse Analysis

The Competition Commission of India’s 2022 ruling against MakeMyTrip marked a watershed moment for the country’s online travel sector. The regulator fined the platform $26 million for imposing price‑parity clauses that prevented hotels from offering lower rates on rival sites, a practice deemed anti‑competitive. Despite publicly stating compliance, Morpheus Research’s latest report suggests the company still manipulates hotel rankings through a covert “price competitiveness score,” effectively preserving the same restrictive dynamics without explicit contractual language. This indirect enforcement raises fresh questions about the efficacy of regulatory oversight in a fast‑moving digital marketplace.

Activist short‑seller reports have become a powerful catalyst for market scrutiny, and Morpheus Research is no exception. By disclosing a short position, the firm not only highlights alleged violations but also flags potential accounting irregularities, including an under‑provisioned receivable from the insolvent airline GoAir and discrepancies between adjusted earnings and International Financial Reporting Standards. Such allegations can amplify volatility in MakeMyTrip’s NASDAQ‑listed shares, prompting investors to reassess risk exposure. The convergence of regulatory non‑compliance and financial opacity intensifies pressure on the company to restore credibility.

Amid the controversy, MakeMyTrip is pursuing a strategic pivot. The firm announced the consolidation of its Indian brands, merging RedBus India into a unified MakeMyTrip India entity, and is exploring a domestic listing to unlock capital for growth. If executed, an Indian‑based IPO could provide fresh funding while signaling a commitment to transparent governance. However, success will hinge on demonstrable compliance with competition laws and clearer financial reporting, factors that will shape both market perception and the platform’s long‑term competitive position.

Morpheus Research report alleges 'anti-competitive' practices by MakeMyTrip despite CCI order

Comments

Want to join the conversation?

Loading comments...